PubMed:32264791 / 1492-1685
Annnotations
LitCovid-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7994 | 12-16 | G_3;PG_10 | denotes | ACE2 |
T7995 | 35-39 | G_3;PG_10 | denotes | Ace2 |
T7996 | 66-83 | CHEBI:48561 | denotes | receptor agonists |
T7997 | 92-96 | G_3;PG_10 | denotes | ACE2 |
LitCovid_AGAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p125242s10 | 92-103 | MPA | denotes | ACE2 action |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-193 | Sentence | denotes | Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS. |
T9 | 0-193 | Sentence | denotes | Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS. |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 0-193 | DRI_Outcome | denotes | Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS. |